fbpx
previous arrow
next arrow
Slider
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED WITHIN THEM, IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014.

Yourgene Health plc
(“Yourgene” or the “Company”)

Acquisition of French distribution channel & Direct Subscription to raise £2.5m

Manchester, UK – 10 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the acquisition of AGX-DPNI S.A.S., a newly formed entity comprised of the NIPT distribution business of AdGeniX S.a.r.L (“AdGeniX”), the Company’s current French distribution partner for its IONA® test, for an initial cash consideration of €2.4m (c. £2.0m) and up to a maximum of €1.7m (c. £1.4m) in cash earn-out payments based on sales growth performance criteria (the “Acquisition”).

In addition, the Company has raised gross proceeds of £2.5 million by way of a direct subscription of 17,482,517 new ordinary shares (the “Direct Subscription”) at 14.3p per ordinary share (the “Placing”) with BGF Investment Management Limited (“BGF”), an existing significant shareholder of the Company. The net proceeds of the Direct Subscription will be used to satisfy the initial cash consideration and for general working capital purposes. Cash-based earn-out payments are expected to be met using the Company’s future cashflows arising out of the Acquisition.

Acquisition highlights
• Acquisition of AGX-DPNI S.A.S., incorporating all customer contracts, current employees and assets that relate to the NIPT distribution business of AdGeniX
• France is a key growth market for NIPT with French Government reimbursement agreed in early 2019 and 75% growth in Yourgene NIPT volume sales in 2019
• Acquisition timed ahead of further anticipated market growth and Yourgene’s launch of the Illumina-based IONA® test
• The Company estimates an immediate EBITDA uplift in first year of c.£0.5m from internalising distributor margins
• NIPT customers in France are mainly large private laboratory networks which have nationwide coverage and better access to new high growth markets in the French-speaking Africa and Middle East regions
• Integrates the NIPT commercial channel in France with the Company’s own direct channel that was acquired through the Elucigene acquisition in April 2019, allowing further range-selling opportunities including further uptake of the reproductive health product portfolio, across public and private health networks

About AdGeniX (https://www.adgenix.fr/)
AdGeniX is a privately held French company, based near Versailles, Paris, with over 25 years’ experience of selling into the cytogenetic and pharmaceutical laboratory markets. They were appointed as distributors for Yourgene’s IONA® test in 2015 and have built a significant market position for the product in France. Since first sales in 2016, NIPT sales volumes have grown rapidly and the Company expects this trend to continue, particularly following the introduction of reimbursement by the French Government for NIPT in 2019 (in France DPNI - dépistage prénatal non-invasif). In addition, the Company expects to further increase NIPT sales volumes in this market following the launch of the Illumina-based IONA® test, for which it recently submitted its technical file to its EU notified body for CE-IVD approval.

Consideration
An initial cash consideration of €2.4m will be payable upon completion. A further two cash payments of €0.6m each will be payable in October 2020 and April 2021 dependent on NIPT sales growth during the period, with a final cash bonus of up to €0.5m due in April 2021 if NIPT sales exceed additional agreed targets. The executive management of AdGeniX are contracted during the earn-out period to ensure a successful transition and customer continuity, with an additional multi-year non-compete provision from completion.

Lyn Rees, CEO of Yourgene, commented: “The Acquisition of our French distributor makes sense for Yourgene on a number of levels. This has an immediate and positive impact on earnings and is an opportunity to fully capitalise on our rising NIPT sales in this growing market alongside our current direct sales of additional reproductive health products. This also allows us to gain maximum benefit from the launch of our Illumina-based IONA® test and increases our ability to range-sell additional content into France and beyond.

“Whilst this provides us with our first direct commercial presence in Europe, and gives us an EU-based presence post-Brexit, it also opens up access to high growth French speaking African and Middle Eastern markets not previously addressed by Yourgene. I would also like to thank BGF for their continued support for our ambitious growth strategy.”
 
Issue of Equity and Total Voting Rights
The New Ordinary Shares will rank pari passu with all existing ordinary shares in the Company. The Direct Subscription is being made under existing shareholder authorities and following Admission, BGF will own 8.1% of the issued ordinary share capital of the Company.

Application will be made to London Stock Exchange for the admission of 17,482,517 New Ordinary Shares to trading on AIM (the “Admission”). It is expected that Admission will occur and that dealings in the shares will commence at 8.00 a.m. on or around Friday, 13 March 2020. The New Ordinary Shares represent approximately 2.9% of the existing issued ordinary share capital of the Company.

Following Admission, the Company will have 616,482,205 ordinary shares in issue. No ordinary shares are held in treasury. The total number of voting rights in the Company will therefore be 616,482,205. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Yourgene Health plc

Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing

Tel: +44 (0)161 669 8122

This email address is being protected from spambots. You need JavaScript enabled to view it.

 Cairn Financial Advisers LLP (NOMAD)

Liam Murray / James Caithie / Ludovico Lazzaretti

 Tel: +44 (0)20 7213 0880

Stifel Nicolaus Europe Limited (Sole Corporate Broker)

Nicholas Moore / Matthew Blawat / Ben Maddison

Tel: +44 (0)20 7710 7600

Walbrook PR Ltd (Media and Investor Relations)

Paul McManus / Lianne Cawthorne 

Tel: +44 (0)20 7933 8780 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Mob: 07980 541 893 Mob: 07584 391 303   

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.  

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.



  • 26 May 2020 - Yourgene COVID-19 testing service launch and business update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene COVID-19 testing service launch and business update

    Manchester, UK – 26 May 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has expanded its laboratory capabilities to offer COVID-19 testing service and it is developing its own COVID-19 test kit and targeting a pipeline of opportunities. In addition, the Company provides an update on its wider business activities.

    Yourgene testing laboratories have

    Read More
  • 20 April 2020 - Year-end Trading update: Revenues increase 86% +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Year-end Trading update: Revenues increase 86%

    Manchester, UK – 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31 March 2020.

    Revenues for the year ended 31 March 2020 were £16.6m (2019: £8.9m), up 86% compared to the previous year, and does not include £0.4m of orders for March that fell into the new financial

    Read More
  • 7 April 2020 - Presentation on ‘Adapting during crisis’ +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Presentation on ‘Adapting during crisis’

    Manchester, UK – 7 April 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that Hayden Jeffreys, Chief Operating Officer of Yourgene Health, will be presenting at 4pm today at the virtual webinar event ‘Adapting during crisis’ hosted by Bruntwood Sci-Tech.

    Bruntwood Sci-Tech will be joined by its customers from across Manchester and Innovation Birmingham who have adapted

    Read More
  • 25 March 2020 - Contract manufacturing agreement for COVID-19 diagnostic test +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Contract manufacturing agreement for COVID-19 diagnostic test

    Manchester, UK – 25 March 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the signing of an agreement for contract manufacturing services with Novacyt S.A. (“Novacyt”, EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, to support the production of COVID-19 diagnostic tests developed by Primerdesign, Novacyt’s molecular diagnostics division.

    Yourgene will make use

    Read More
  • 10 March 2020 - Acquisition of French distribution channel & Direct Subscription to raise £2.5m +

    THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED WITHIN THEM, IS RESTRICTED AND IS NOT FOR PUBLIC RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
     
    THIS ANNOUNCEMENT CONTAINS
    Read More
  • 17 February 2020 - CE Marking Technical File submission +

    Yourgene Health plc
    (“Yourgene” or the “Company”)

    CE Marking Technical File submission

    Manchester, UK – 17 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has submitted its CE Marking Technical File for the Illumina-based IONA ® test to its EU notified body, BSI Netherlands.

    BSI Netherlands will now audit the CE Marking Technical File and if accepted will issue a European CE Marking Certificate. As soon as regulatory approvals are received
    Read More
  • 14 February 2020 - Medilink Award win for Outstanding Achievement  +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Medilink Award win for Outstanding Achievement

    Manchester, UK – 14 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won the Outstanding Achievement Award at the Medilink North of England Healthcare Business Awards 2020, held at the Lowry Hotel in Manchester , yesterday.

    The Outstanding Achievement Award is presented to a Company for an achievement that has had a significant or vital

    Read More
  • 14 February 2020 - TGA approves DPYD for sale in Australia +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    TGA approves DPYD for sale in Australia

    Southern Cross, Yourgene’s Australian distributor , to sell the chemotoxicity diagnostic assay in the Territory

    Manchester, UK – 14 February 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its chemotoxicity diagnostics assay – Elucigene DPYD - which tests to identify cancer patients at risk of lethal side effects from chemotherapy, has been approved for sale in Australia (‘the

    Read More
  • 5 December 2019 - The Healthcare+ Expo Taiwan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    The Healthcare+ Expo Taiwan

    Manchester, UK – 5 December 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be exhibiting and presenting at The Healthcare+ Expo Taiwan, from the 5-8 December 2019 at stand R241, Hall 2 in the Taipei Nangang Exhibition Centre, Taiwan City, Taiwan.

    The Expo brings together over 600 exhibitors, working in the advanced medicine and leading technology space

    Read More
  • 2 December 2019 - Half-year Report +

    This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

    Yourgene Health plc 

    (“Yourgene”, the “Company” or the “Group”) 

    Half-year Report 

    Manchester, UK – 2 December 2019: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half year report for the six months ended 30 September 2019, in line with expectations. 

    The results reflect strong organic growth as well as a

    Read More
  • 29 November 2019 - Bionow Double Award Wins +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Bionow Double Award Wins

    Manchester, UK – 29 November 2019 : Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has won Bionow Investment Deal of Year and Bionow Company of the Year at the 18th Annual Bionow Awards ceremony, held at The Mere Golf Resort & Spa in Cheshire yesterday.

    The Bionow Investment Deal of Year, sponsored by QIAGEN, is an award presented to

    Read More
  • 28 November 2019 - Opening of New Facilities and Corporate HQ  +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Opening of New Facilities and Corporate HQ  

    Manchester, UK – 28 November 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the official opening of its newly integrated facilities and corporate HQ at Citylabs 1.0, in the centre of Manchester’s genomics campus, and continued expansion with a planned further increase in headcount at the Company’s UK headquarters.

    The establishment of the new Company

    Read More
  • 31 October 2019 - Launch of Yourgene Flex™ Analysis Software +

    Yourgene Health plc
    (“Yourgene” or the “Group” or the “Company”)

    Launch of Yourgene Flex ™ Analysis Software

    Manchester, UK 31 October 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it has launched Yourgene Flex ™ Analysis Software, a medical grade, configurable bioinformatics software platform to further support the Company’s product diversification ambitions.

    Building on the excellent bioinformatics technology and expertise deployed in the Group’s IONA® Software, Yourgene Flex ™ Analysis Software is a modular next-generation

    Read More
  • 15 October 2019 - American Society of Human Genetics Annual Meeting attendance +

    Yourgene Health plc

    (“Yourgene” or the “Group”)

    American Society of Human Genetics Annual Meeting attendance

    Manchester, UK – 15 October 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it will be exhibiting at the American Society of Human Genetics (“ASHG”) Annual Meeting in Houston, Texas which runs from Tuesday 15 October to Saturday 19 October 2019 (Booth no. 101).

    The ASHG Annual Meeting is the first time the Company has taken an

    Read More
  • 14 October 2019 - Half year trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group”)

    Half year trading update

    Manchester, UK – 14 October 2019:  Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides a positive trading update for the six months to 30 September 2019.

    Revenues for the six months to 30 September 2019 were £7.8m, up 98% on the equivalent prior year period (six months to 30 September 2018: £3.9m), and in line with management expectations. International revenues continue to show

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen